| How much does it cost to research and develop a new drug? A systematic review and assessment M Schlander, K Hernandez-Villafuerte, CY Cheng, J Mestre-Ferrandiz, ... Pharmacoeconomics 39, 1243-1269, 2021 | 160 | 2021 |
| Cost-effectiveness of colorectal cancer screening strategies—a systematic review T Ran, CY Cheng, B Misselwitz, H Brenner, J Ubels, M Schlander Clinical gastroenterology and hepatology 17 (10), 1969-1981. e15, 2019 | 129 | 2019 |
| Do certified cancer centers provide more cost‐effective care? A health economic analysis of colon cancer care in Germany using administrative data CY Cheng, T Datzmann, D Hernandez, J Schmitt, M Schlander International journal of cancer 149 (10), 1744-1754, 2021 | 34 | 2021 |
| Determinants of heterosexual men's demand for long-acting injectable pre-exposure prophylaxis (PrEP) for HIV in urban South Africa CY Cheng, M Quaife, R Eakle, MA Cabrera Escobar, P Vickerman, ... BMC public health 19, 1-9, 2019 | 23 | 2019 |
| Impact of a multiplex PCR point-of-care test for influenza A/B and respiratory syncytial virus on an acute pediatric hospital ward AI Vecino-Ortiz, SD Goldenberg, ST Douthwaite, CY Cheng, RE Glover, ... Diagnostic microbiology and infectious disease 91 (4), 331-335, 2018 | 19 | 2018 |
| Evaluating key characteristics of ideal colorectal cancer screening modalities: the microsimulation approach A Deibel, L Deng, CY Cheng, M Schlander, T Ran, B Lang, N Krupka, ... Gastrointestinal endoscopy 94 (2), 379-390. e7, 2021 | 12 | 2021 |
| Modeling respiratory syncytial virus adult vaccination in the United States with a dynamic transmission model T Van Effelterre, N Hens, LJ White, S Gravenstein, AR Bastian, ... Clinical Infectious Diseases 77 (3), 480-489, 2023 | 10 | 2023 |
| Survival and comorbidities in lung cancer patients: Evidence from administrative claims data in Germany D Hernandez, C Cheng, K Hernandez-Villafuerte, M Schlander Oncology Research 30 (4), 173, 2022 | 8 | 2022 |
| The health economics of cancer screening in Germany: which population-based interventions are cost-effective? M Schlander, CY Cheng, T Ran Bundesgesundheitsblatt-Gesundheitsforschung-Gesundheitsschutz 61, 1559-1568, 2018 | 4 | 2018 |
| Gesundheitsökonomie der Krebsfrüherkennung in Deutschland: Welche Interventionen sind kosteneffektiv bei bevölkerungsweiter Umsetzung M Schlander, CY Cheng, T Ran Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 61 (12), 1559-68, 2018 | 4 | 2018 |
| Budget impact of introducing once-every-6-months paliperidone palmitate in US health care plans H Phelps, D Lin, A Keenan, A Raju, D Huang, CY Cheng, C Benson Journal of Managed Care & Specialty Pharmacy 29 (3), 303-313, 2023 | 3 | 2023 |
| Predicted Public Health and Economic Impact of Respiratory Syncytial Virus Vaccination with Variable Duration of Protection for Adults≥ 60 Years in Belgium MJ Postma, CY Cheng, NC Buyukkaramikli, L Hernandez Pastor, ... Vaccines 11 (5), 990, 2023 | 2 | 2023 |
| Modeling the natural history and screening effects of colorectal cancer using both adenoma and serrated neoplasia pathways: the development, calibration, and validation of a … CY Cheng, S Calderazzo, C Schramm, M Schlander MDM Policy & Practice 8 (1), 23814683221145701, 2023 | 2 | 2023 |
| A Real World Evidence (RWE) Approach To Characterising An Ultra-Rare Disease (URD) Cohort of Metastatic Uveal Melanoma (MUM) Patients Within National Health Service England (NHSE) M Schwenkglenks, G Alamgir, C Cheng, EJ Adams, T Toward Value in Health 20 (9), A730, 2017 | 1 | 2017 |
| Would initiating colorectal cancer screening from age of 45 be cost-effective in Germany? An individual-level simulation analysis MW Lwin, CY Cheng, S Calderazzo, C Schramm, M Schlander Frontiers in Public Health 12, 1307427, 2024 | | 2024 |
| WOULD INITIATING COLORECTAL CANCER SCREENING FROM AGE OF 45 BE COST-EFFECTIVE IN GERMANY? AN INDIVIDUAL-LEVEL SIMULATION ANALYSIS M Lwin, CY Cheng, S Calderazzo, C Schramm, M Schlander VALUE IN HEALTH 26 (12), S121-S122, 2023 | | 2023 |
| MSR7 Incorporating External Data to Inform Overall Survival Extrapolation: A Review of NICE Health Technology Appraisals for Oncology Drugs CY Cheng, DV Tomori, L Fernandes, N Buyukkaramikli, J Holden, F Pan Value in Health 26 (12), S394, 2023 | | 2023 |
| EE368 Would Initiating Colorectal Cancer Screening from Age of 45 Be Cost-Effective in Germany? An Individual-Level Simulation Analysis M Lwin, CY Cheng, S Calderazzo, C Schramm, M Schlander Value in Health 26 (12), S121-S122, 2023 | | 2023 |
| MSR140 Current Trends in Survival Extrapolation Methods: A Review of NICE Health Technology Appraisals for Oncology Drugs L Fernandes, DV Tomori, CY Cheng, N Buyukkaramikli, J Holden, F Pan Value in Health 26 (12), S420, 2023 | | 2023 |
| Reply to Standaert, B. Comment on “Postma et al. Predicted Public Health and Economic Impact of Respiratory Syncytial Virus Vaccination with Variable Duration of Protection for … MJ Postma, CY Cheng, NC Buyukkaramikli, L Hernandez Pastor, ... Vaccines 11 (11), 1673, 2023 | | 2023 |
